AU2022214939A1 - Hhla2 binding agents with novel activity - Google Patents

Hhla2 binding agents with novel activity Download PDF

Info

Publication number
AU2022214939A1
AU2022214939A1 AU2022214939A AU2022214939A AU2022214939A1 AU 2022214939 A1 AU2022214939 A1 AU 2022214939A1 AU 2022214939 A AU2022214939 A AU 2022214939A AU 2022214939 A AU2022214939 A AU 2022214939A AU 2022214939 A1 AU2022214939 A1 AU 2022214939A1
Authority
AU
Australia
Prior art keywords
hhla2
antibody
binding
antigen
binding agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022214939A
Other languages
English (en)
Inventor
Detlev BINISZKIEWICZ
Nadthakarn BOLAND
Scott Chappel
Bijan Etemad-Gilbertson
Nels NIELSON
Bianka Prinz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NextPoint Therapeutics Inc
Original Assignee
NextPoint Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NextPoint Therapeutics Inc filed Critical NextPoint Therapeutics Inc
Publication of AU2022214939A1 publication Critical patent/AU2022214939A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Catalysts (AREA)
AU2022214939A 2021-01-28 2022-01-28 Hhla2 binding agents with novel activity Pending AU2022214939A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163142832P 2021-01-28 2021-01-28
US63/142,832 2021-01-28
PCT/US2022/014423 WO2022165258A1 (en) 2021-01-28 2022-01-28 Hhla2 binding agents with novel activity

Publications (1)

Publication Number Publication Date
AU2022214939A1 true AU2022214939A1 (en) 2023-07-20

Family

ID=82652818

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022214939A Pending AU2022214939A1 (en) 2021-01-28 2022-01-28 Hhla2 binding agents with novel activity

Country Status (11)

Country Link
US (1) US20250270323A1 (https=)
EP (1) EP4284431A4 (https=)
JP (1) JP2024509501A (https=)
KR (1) KR20230135637A (https=)
CN (1) CN116981476A (https=)
AU (1) AU2022214939A1 (https=)
BR (1) BR112023014826A2 (https=)
CA (1) CA3207494A1 (https=)
IL (1) IL304584A (https=)
MX (1) MX2023008182A (https=)
WO (1) WO2022165258A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL326764A (en) * 2023-09-08 2026-04-01 Nextpoint Therapeutics Inc Antibody-drug conjugates
CN119841949A (zh) * 2023-10-17 2025-04-18 科辉智药(深圳)新药研究中心有限公司 一种抗人hhla2的纳米抗体及其应用
CN121005781A (zh) * 2024-05-24 2025-11-25 合肥天港免疫药物有限公司 高亲和力b7h7抗体或其抗原结合片段及其用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10280208B2 (en) * 2014-04-30 2019-05-07 Albert Einstein College Of Medicine TMIGD2 and its derivatives as blockers or binders of cancer-expressed HHLA2 for immunotherapies
EA202090003A1 (ru) * 2017-07-06 2020-06-18 Мерус Н.В. Связывающие молекулы, модулирующие биологическую активность, которую проявляет клетка
KR20210007959A (ko) * 2018-04-06 2021-01-20 다나-파버 캔서 인스티튜트 인크. Hhla2 수용체로서의 kir3dl3, 항-hhla2 항체, 및 이들의 용도

Also Published As

Publication number Publication date
KR20230135637A (ko) 2023-09-25
EP4284431A4 (en) 2025-01-15
BR112023014826A2 (pt) 2023-10-03
JP2024509501A (ja) 2024-03-04
CN116981476A (zh) 2023-10-31
US20250270323A1 (en) 2025-08-28
IL304584A (en) 2023-09-01
MX2023008182A (es) 2023-09-15
WO2022165258A1 (en) 2022-08-04
EP4284431A1 (en) 2023-12-06
CA3207494A1 (en) 2022-08-04

Similar Documents

Publication Publication Date Title
JP7153626B2 (ja) 抗ヒト４－１ｂｂ抗体およびその使用
TWI883044B (zh) 使用her3抗原結合分子的癌症之治療及預防
TWI564306B (zh) 雙特異性抗體
TW202039575A (zh) 新穎之抗ｃｃｒ８抗體
KR20200139725A (ko) Her3 항원 결합 분자
CN110545845A (zh) 抗cd33抗体药剂
TW201909926A (zh) Ｂ７ｈ３抗體－藥物偶聯物及其醫藥用途
JP2023541473A (ja) 抗４－１ｂｂ－抗ｐｄ－ｌ１二重特異性抗体、ならびにその医薬組成物および使用
US20250270323A1 (en) Hhla2 binding agents with novel activity
JP2023524102A (ja) Ａｂｃｂ５に特異的な抗体およびその使用
WO2019086574A1 (en) Cd47 and cd33 antigen-binding molecules
US20210277139A1 (en) Ifn-gamma-inducible regulatory t cell convertible anti-cancer (irtca) antibody and uses thereof
WO2022149050A2 (en) Bispecific epitope binding protein comprising anti-4-1bb antibody and pd-1 protein or fragments thereof and use thereof
JP2023541853A (ja) Ｐｄ－１ポリペプチド変異体
US20250138018A1 (en) T cell and nk cell engagers
HK40102688A (zh) 具有新型活性的hhla2结合剂
WO2020204033A1 (ja) がん治療用医薬
US20250171533A1 (en) Kir3dl3 inhibitors and immune cell activating agents
WO2025175056A1 (en) Multispecific antibodies or antigen binding fragments thereof to b7-h7 and immune effector cell antigens
TW202523694A (zh) 抗muc16抗體及其用途